This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Osteopetrosis (Marble Bone Disease)골화석증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q78.2 (osteopetrosis) | Special Copayment Reduction: V229 (rare disease)
B. SynonymsOsteopetrosis | Albers-Schönberg disease
C. Adult onsetLikelihood of first onset in adulthood moderate (benign form) / very low (malignant form) — the autosomal recessive malignant form (infantile) is almost always diagnosed early because of fatal complications in infancy; the autosomal dominant benign form (Albers-Schönberg type) is asymptomatic or mild, so incidental detection in adulthood is common; the intermediate form (CAII deficiency) presents in childhood to adolescence.
1. History1904 first X-ray description by Albers-Schönberg → 'marble bone disease' → 1968 Walker identified osteoclast dysfunction → 1995 TCIRG1, 2001 CLCN7 mutations identified → in the 2000s hematopoietic stem cell transplantation (HSCT) became established as standard treatment for the malignant form.
2. CausesDefect in osteoclast function. AR malignant form: mutations in TCIRG1 (about 50%), CLCN7 (about 15%), OSTM1, SNX10, PLEKHM1, etc. AD benign form: heterozygous CLCN7 mutations. CAII-deficient form: CA2 mutations (with renal tubular acidosis). RANKL/RANK-deficient form (impaired osteoclast differentiation).
3. GeneticsMalignant form: AR; TCIRG1 (11q13.2), CLCN7 (16p13.3), OSTM1, SNX10, etc. Benign form: AD; heterozygous CLCN7 mutations (50% penetrance). Intermediate form (juvenile form): AR; CA2 (8q21.2). Rare forms: TNFSF11 (RANKL), TNFRSF11A (RANK) deficiency (osteoclast-poor form). Variant type is important for predicting HSCT response and prognosis.
4. General epidemiologyPrevalence of the AR malignant form about 1/250,000 births. AD benign form about 1/20,000. The CAII-deficient form is relatively common among people of North African descent. An estimated 300~500 new diagnoses of the malignant form per year worldwide. Equal occurrence in males and females (AR). Many case reports in Korea.
5. PathophysiologyFailure of bone remodeling due to defects in osteoclast acidification (H⁺-ATPase, TCIRG1) and chloride channel (ClC-7, CLCN7) function required for bone resorption. The marrow cavity is filled with fibrotic and ossified tissue → hematopoietic failure (pancytopenia). Bones are hard but fragile (accumulation of immature woven bone). Nerve compression due to narrowing of cranial nerve canals and the spinal canal.
6. SymptomsMalignant form: hematopoietic failure in infancy (anemia, thrombocytopenia, neutropenia), recurrent infections, hepatosplenomegaly, cranial nerve palsies (blindness, hearing loss, facial palsy), hypocalcemic seizures. Benign form: mostly asymptomatic; fractures, mandibular osteomyelitis, headache, mild anemia possible.
7. SignsX-ray: marked generalized increase in bone density, bone-within-bone appearance, sandwich vertebra. Erlenmeyer flask deformity (distal femur). Pancytopenia. Elevated serum ALP, LDH and CK-BB. Signs of cranial nerve palsy. Splenomegaly (extramedullary hematopoiesis).
8. ScreeningNewborns with a family history: blood count + X-ray (whole skeleton). Newborn screening (some countries). In infants with pancytopenia and hepatosplenomegaly, a whole-skeleton X-ray survey gives diagnostic clues. Gene panel testing (TCIRG1, CLCN7, etc.) for confirmation and assessment of HSCT eligibility.
9. DiagnosisX-ray (generalized skeletal hyperdensity, bone-within-bone). CBC + reticulocytes, serum ALP, calcium and phosphorus. Bone marrow biopsy (confirmation of reduced hematopoiesis). Confirmation: NGS gene panel (TCIRG1, CLCN7, OSTM1, etc.). Prenatal diagnosis (CVS/amniocentesis). Osteoclast function assays (assessment of acid secretion and bone resorption). Ophthalmologic, audiologic and cranial nerve evaluation.
10. TreatmentMalignant form: hematopoietic stem cell transplantation (HSCT) is the only curative treatment — HSCT from a matched donor reconstitutes osteoclast precursor cells. Osteoclast support: interferon-γ (IFN-γ), calcitriol, prednisolone. Transfusion and G-CSF (hematopoietic support). Cranial nerve decompression. Benign form: symptomatic treatment (correction of hypocalcemia, antibiotics and surgery for mandibular osteomyelitis).
11. PrognosisAR malignant form: without HSCT, most die before age 10. Long-term survival after HSCT about 50~70% (depending on donor and timing). Cranial nerve damage recovers incompletely even after HSCT. Benign form: life expectancy close to normal. RANKL-deficient form: HSCT is ineffective (other treatment needed).
12. PreventionGenetic counseling and prenatal genetic diagnosis (CVS). Early testing of newborns with a family history for early HSCT (before nerve damage occurs). Prevention of hypocalcemia (calcium, vitamin D). Infection prevention (PCP prophylaxis, vaccines). Regular imaging evaluation so as not to miss the timing for decompression surgery.
13. ReferencesStark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009 … and 9 other papers

1. History

The history of osteopetrosis began with the development of radiology in the early 20th century. In 1904, the German radiologist Heinrich Ernst Albers-Schönberg first described by X-ray and reported a patient showing a marked increase in radiopacity of the entire skeleton. Because the bones looked like marble, it was given the nickname 'marble bone disease', and it later also came to be called 'Albers-Schönberg disease'. This first description is presumed to correspond to the autosomal dominant benign form of osteopetrosis.

In the first half of the 20th century, the paradoxical phenomenon was observed clinically that in osteopetrosis, fractures occur easily despite high bone density, and hematopoietic failure and nerve compression complications are present. This was an important clinical observation suggesting that bone strength and density do not necessarily coincide and that bone remodeling is essential for maintaining the mechanical properties of bone. In 1938, Kaplan and colleagues described the pathological finding that in patients with osteopetrosis the bone marrow space is filled with fibrotic tissue and primitive bone, suppressing hematopoiesis.

The key elucidation of the pathophysiology came from Walker's 1968 studies of osteoclast function. Using osteopetrotic mouse models (op/op mice, etc.), Walker showed in cross-circulation experiments that transplantation of hematopoietic stem cells from normal mice could cure osteopetrosis; this was a landmark experiment that proved osteoclasts are cells of hematopoietic origin and established that the core defect of osteopetrosis is osteoclast dysfunction. This discovery later became the scientific basis for attempting hematopoietic stem cell transplantation (HSCT) as treatment in human patients with osteopetrosis.

Clinical application of HSCT was first performed in the Netherlands in 1977 in an infant with autosomal recessive malignant osteopetrosis and showed successful results. Thereafter, HSCT became established as the only curative treatment for the AR malignant form. In the era of molecular genetics, mutations in the TCIRG1 gene (encoding proton pump subunit a3) in 2000 and mutations in the CLCN7 gene (encoding the chloride channel CLC-7) in 2001 were identified as major causes of the AR malignant form. Subsequently, as defects in several genes such as OSTM1, SNX10, PLEKHM1 and CA2 were found to be associated with respective subtypes of osteopetrosis, molecular diagnosis became central to clinical management and prognosis prediction. Gene therapy (gene correction of hematopoietic stem cells using viral vectors) is being studied at the preclinical and early clinical stages and is expected to be a new treatment option in the future.


2. Causes

Osteopetrosis is a genetic disorder in which bone remodeling does not take place because of a defect in the bone-resorbing function of osteoclasts, resulting in markedly increased bone density and abnormal bone structure. It is classified into several subtypes according to the causative gene, and the main genes encode proteins involved in acidification during osteoclastic bone resorption.

The most common causative gene of autosomal recessive malignant osteopetrosis (AR malignant/infantile osteopetrosis) is TCIRG1 (T cell immune regulator 1, 11q13.2), accounting for about 50% of all cases. TCIRG1 encodes the a3 subunit of the proton pump (vacuolar H⁺-ATPase, V-ATPase) located in the ruffled border membrane of osteoclasts; with this defect, osteoclasts cannot acidify the resorption space (Howship lacuna), so mineral dissolution and bone matrix degradation do not occur. The second most common gene is CLCN7 (chloride channel 7, 16p13.3), accounting for about 15% of the AR malignant form and most of the AD benign form (Albers-Schönberg disease). The CLC-7 chloride channel is essential for electrically compensating the proton flux generated by V-ATPase, and when deficient, V-ATPase function is secondarily inhibited. In addition, variants in genes such as OSTM1 (β-subunit of CLC-7, 6q21), SNX10 (sorting nexin 10, 7p15.2), PLEKHM1 (vesicle transport, 17q21.31) and LYST (Chediak-Higashi-associated) account for the remainder of the AR malignant form.

The carbonic anhydrase II-deficient form (CA2 mutations) is caused by mutations in the CA2 gene at 8q21.2; acid production in osteoclasts and acid excretion in the renal tubules are impaired simultaneously, resulting in a juvenile form of osteopetrosis accompanied by renal tubular acidosis and cerebral calcification. A relatively common founder mutation has been reported in North African Arab populations.

Osteoclast differentiation defect forms: In RANKL (TNFSF11) or RANK (TNFRSF11A) gene deficiency, osteoclast differentiation itself does not occur, so osteoclasts in tissue are few or almost absent. This form is not corrected by HSCT (because the RANKL/RANK-deficient cells derive from stromal cells), and administration of recombinant RANKL is at the research stage.


3. Genetics

The mode of inheritance of osteopetrosis differs by subtype. The AR malignant form (infantile) is autosomal recessive and manifests only when one pathogenic variant is inherited from each parent. Each parent is a heterozygous carrier and usually asymptomatic, and the disease manifests in 25% of children. The AD benign form (Albers-Schönberg type) is autosomal dominant, caused by heterozygous mutations in the CLCN7 gene; penetrance is incomplete at about 50%, so clinical expression within families varies. Symptomatic members and asymptomatic carriers can coexist in the same family.

The TCIRG1 gene is located on the long arm of chromosome 11 (11q13.2) and encodes the V-ATPase a3 subunit. A variety of mutations have been reported, including frameshift, nonsense, splicing and missense variants, and founder mutations have been identified in some populations (Costa Rica, Czech Republic, Scandinavia). The CLCN7 gene is located on the short arm of chromosome 16 (16p13.3) and encodes the CLC-7 chloride channel. In the AR malignant form, homozygous or compound heterozygous CLCN7 variants act, whereas in the AD benign form, heterozygous dominant negative variants act.

Molecular diagnosis is central to clinical management and determination of HSCT eligibility. Because the RANKL/RANK-deficient form does not respond to HSCT, confirmation of the causative gene is mandatory before HSCT. Patients with OSTM1 mutations have prominent neurological involvement, and neurological progression may continue even after HSCT, so the prognosis is poor. Understanding genotype-phenotype correlations is essential for treatment decisions and prognostic counseling.

In families with the AR malignant form, prenatal diagnosis directly detects the familial variant by chorionic villus sampling (CVS, at 11~14 weeks of gestation) or amniocentesis (at 15~20 weeks of gestation). Preimplantation genetic testing (PGT-M) is also theoretically possible. Carrier couples (AR type) need thorough genetic counseling with a specialist when planning a family.


4. General epidemiology

The prevalence of osteopetrosis varies greatly by type. The prevalence of the AR malignant (infantile) form is estimated at about 1 in 250,000 births, and about 300~500 new patients are estimated to occur worldwide each year. The prevalence of the AD benign form (Albers-Schönberg disease) is much higher at about 1/20,000, and because clinical symptoms are mild, many patients are expected to be found incidentally or remain undiagnosed.

The AR malignant form occurs equally in males and females and is reported in all ethnic groups and regions. Relatively higher frequencies are reported in populations where consanguineous marriage is common (the Middle East, North Africa, parts of the Mediterranean). The CAII-deficient form (juvenile form) is reported at relatively high frequency among North African Arabs because of a founder mutation. TCIRG1 founder mutations have been reported in Scandinavia, Costa Rica and the Czech Republic. The AD benign form is caused by heterozygous CLCN7 variants, occurs in all ethnic groups, and shows variable expression within families.

In Korea, patients registered under the rare disease Special Copayment Reduction (V229) are being reported, and intensive treatment including HSCT is provided at large centers such as Asan Medical Center, Samsung Medical Center and Seoul National University Hospital. AR malignant form cases with TCIRG1 and CLCN7 mutations have also been reported in Korea, and early diagnosis and HSCT are contributing to improved survival.

Without treatment, the AR malignant form has a very high mortality before age 10. HSCT is the only curative treatment, but securing a suitable donor and transplant-related complications are major challenges. Worldwide, an important public health problem is that a considerable proportion of newly occurring AR malignant form patients each year are not diagnosed in time or cannot access HSCT.


5. Pathophysiology

The core pathophysiology of osteopetrosis is the failure of bone remodeling due to a defect in the bone-resorbing function of osteoclasts. Normally, osteoclasts form a ruffled border on the bone surface, make the underlying resorption space (Howship lacuna) an acidic environment of pH 4~5 via V-ATPase (H⁺-ATPase) to dissolve bone mineral (hydroxyapatite), and then degrade the bone matrix (collagen) with proteolytic enzymes such as cathepsin K.

With TCIRG1 or CLCN7 defects, this acidification process is fundamentally impossible. The V-ATPase a3 subunit encoded by TCIRG1 actively transports protons (H⁺) across the ruffled border membrane into the resorption space, and when this function is lost, acid production itself is impossible. CLCN7 (CLC-7) is a channel that transports Cl⁻ into the resorption space to electrically compensate for H⁺ transport by V-ATPase; when deficient, V-ATPase is also secondarily inhibited by the membrane potential difference. Consequently, both bone mineral dissolution and matrix degradation become impossible.

When bone remodeling does not occur, woven bone formed from the fetal period is not resorbed but accumulates, markedly increasing bone density. At the same time, the medullary cavity is filled with unresorbed bone tissue and fibrotic matrix, leaving no space for hematopoietic tissue to grow normally, and pancytopenia develops. To compensate for hematopoietic failure, extramedullary hematopoiesis is activated in the spleen, liver, lymph nodes and elsewhere, causing hepatosplenomegaly.

Although bone density is high, immature woven bone predominates because there is no bone remodeling, so paradoxically mechanical strength is reduced. Thus paradoxical fragility, with fractures occurring even after minor trauma, is characteristic. Overgrowth and hyperdensity of the skull, facial bones and spine narrow the foramina through which the cranial nerves pass, causing cranial nerve palsy complications such as optic nerve compression (blindness), auditory nerve compression (hearing loss) and facial nerve compression (facial palsy).

In CA2 deficiency, carbonic anhydrase II in osteoclasts cannot catalyze the reaction CO₂ + H₂O → H₂CO₃ → H⁺ + HCO₃⁻, reducing the H⁺ supply, so the substrate of V-ATPase is insufficient and acidification does not occur. At the same time, impaired acid excretion in the renal tubules is accompanied by metabolic acidosis (renal tubular acidosis type II), and in the brain, carbonic anhydrase deficiency causes deposition of calcium carbonate, resulting in cerebral calcification.


6. Symptoms

The clinical symptoms of osteopetrosis differ dramatically by type. The AR malignant (infantile) form is a fatal disease in which serious complications appear within months after birth, whereas the AD benign form (Albers-Schönberg type) is often asymptomatic until adulthood or shows only mild symptoms.

Symptoms of the AR malignant (infantile) form: The most serious and threatening symptoms are complications of hematopoietic failure. Loss of marrow space makes normal hematopoiesis impossible, causing severe anemia, with pallor, feeding difficulty and growth retardation due to anemia. Bleeding tendency due to thrombocytopenia (petechiae, bruising, nosebleeds) and recurrent infections due to neutropenia (pneumonia, sepsis) are life-threatening. Hepatosplenomegaly, as evidence of extramedullary hematopoiesis, causes abdominal distension and a palpable mass. Cranial nerve compression causes optic atrophy (risk of progressive blindness), auditory nerve damage (hearing loss), facial nerve palsy (facial asymmetry, difficulty closing the eyes) and paralysis of the masticatory muscles. Hypocalcemia occurs because loss of osteoclast function prevents release of calcium from bone, and can cause seizures, tetany and hypocalcemic heart failure.

Symptoms of the AD benign form (Albers-Schönberg type): Mostly asymptomatic and found incidentally on radiography. When symptomatic, recurrent fractures (especially of the lower limb bones), mandibular osteomyelitis (likely to occur after tooth extraction), mild anemia, headache and cranial nerve damage (decreased vision, facial palsy) may occur. Clinical expression varies greatly even within the same family.

Symptoms of the CAII-deficient form (juvenile form): From childhood, osteopetrotic findings, renal tubular acidosis (growth retardation, rickets) and cerebral calcification are combined. Intellectual disability is present in some patients.


7. Signs

The physical, laboratory and radiological signs of osteopetrosis are characteristic, as follows.

Radiological signs: On plain X-ray, marked radiopacity (sclerosis) of the entire skeleton is the most characteristic. The bone-within-bone (endobone) appearance, in which another bone appears inside the bone, is observed in the vertebral bodies and long bones. In the spine, the upper and lower endplates are sclerotic while the central portion is relatively less sclerotic, producing the sandwich vertebra or rugger-jersey vertebra appearance. In the distal femur and proximal tibia, Erlenmeyer flask deformity — a flask-shaped widening resulting from failure of normal narrowing of the medullary canal in the metaphyseal region — is observed. The skull becomes thickened and the skull base becomes hyperdense. Fractures occur repeatedly, especially in the femur.

Hematological signs: The complete blood count (CBC) shows normocytic normochromic anemia or hemolytic findings, thrombocytopenia and neutropenia. The peripheral blood smear shows nucleated RBCs and immature granulocytes (leukoerythroblastosis), which are evidence of extramedullary hematopoiesis.

Biochemical signs: Serum alkaline phosphatase (ALP) is markedly elevated, in proportion to increased osteoclast number and activity. Serum LDH and CK-BB (brain-type creatine kinase) may also be elevated. Serum calcium may be decreased (hypocalcemia), and parathyroid hormone (PTH) is reactively elevated. In the CA2-deficient form, arterial blood gas analysis shows non-anion gap metabolic acidosis and impaired urinary acidification (urine pH > 5.5).

Neurological signs: Funduscopy may show optic disc pallor and visual field defects (loss of central or peripheral vision). Audiological testing reveals conductive, sensorineural or mixed hearing loss. Clinical findings of cranial nerve palsy (facial nerve VII, optic nerve II, auditory nerve VIII) appear. MRI/CT shows narrowing of the skull base and foramina.


8. Screening

Population-wide screening for osteopetrosis is not performed. However, systematic screening evaluation is important in high-risk groups with a family history, infants with pancytopenia and hepatosplenomegaly, and patients with incidentally found bone density abnormalities.

Screening of newborns with a family history: Siblings of patients with AR malignant osteopetrosis (25% risk when both parents are carriers) undergo a complete blood count, serum ALP measurement and a whole-body skeletal X-ray survey (skeletal survey) immediately after birth. If abnormal findings are found, immediate genetic confirmation and HSCT review begin. Early diagnosis is decisive in determining the optimal timing of HSCT (before cranial nerve damage occurs).

Screening of infants with pancytopenia and hepatosplenomegaly: Osteopetrosis must be included in the differential diagnosis of causes of infantile pancytopenia. If a bone density abnormality is found on plain chest or abdominal X-ray, an immediate whole-body skeletal X-ray survey and genetic testing are performed. Confirmation of reduced hematopoietic tissue and bone tissue encroachment on bone marrow biopsy is of decisive help in diagnosis.

Incidentally found increased bone density: If generalized increased bone density is found in an adult on an X-ray or CT taken for another reason, the AD benign form of osteopetrosis is suspected, and family history review, serum ALP measurement and X-ray survey of the family are performed.

Gene panel testing: If the AR malignant form is suspected, the causative gene is identified by NGS-based osteopetrosis panel testing including TCIRG1, CLCN7, OSTM1, SNX10, PLEKHM1, CA2, TNFSF11 and TNFRSF11A. This is essential for HSCT eligibility (HSCT ineffective in RANKL/RANK deficiency), prognosis prediction and planning of prenatal diagnosis.


9. Diagnosis

Diagnosis of osteopetrosis is made through a systematic approach integrating clinical findings, radiological imaging, blood tests and molecular genetic analysis.

Clinical evaluation: Age at onset, systemic symptoms (pallor, growth retardation, recurrent infections), family history, cranial nerve function (vision, hearing, facial movement) and fracture history are systematically evaluated. In the AR malignant form, pallor, feeding difficulty and hepatosplenomegaly within the first months of life are the main initial complaints.

Radiological imaging: A whole-body skeletal X-ray survey is the most important diagnostic tool. Bone-within-bone, sandwich vertebra and Erlenmeyer flask deformity are characteristic. CT is used to assess the degree of narrowing of the skull base and foramina and for surgical planning, and brain CT can confirm the cerebral calcification of the CA2-deficient form. MRI is used to evaluate intracranial nerve compression, spinal cord abnormalities and bone marrow tissue.

Blood tests: CBC + peripheral blood smear (pancytopenia, nucleated RBCs, leukoerythroblastosis), serum ALP (markedly elevated), LDH, CK-BB, serum calcium, phosphorus and PTH, 25-OH vitamin D, and blood gas analysis in the CA2-deficient form (metabolic acidosis). Reticulocyte count (degree of extramedullary hematopoiesis) and regular follow-up CBC are used to evaluate treatment response.

Bone marrow biopsy: The degree of damage to hematopoietic tissue, fibrosis, and the number and morphological abnormalities of osteoclasts are assessed. Osteoclasts may be numerous but with abnormal ruffled border formation, or, in the RANKL/RANK-deficient form, the number of osteoclasts itself is reduced or absent.

Molecular genetic diagnosis: Analysis with an NGS-based osteopetrosis gene panel (TCIRG1, CLCN7, OSTM1, SNX10, PLEKHM1, CA2, TNFSF11, TNFRSF11A, etc.) is the standard. Identifying the causative gene is essential for ① determining HSCT eligibility (excluding RANKL/RANK deficiency), ② confirming the poor prognosis of OSTM1 deficiency, and ③ planning prenatal diagnosis. Parental genetic testing is needed to confirm carrier status and AR inheritance.

Ophthalmologic and audiologic evaluation: Optic nerve function is quantitatively assessed with visual acuity, visual field, funduscopy and visual evoked potential (VEP) testing. The degree of hearing loss is determined by pure-tone audiometry and ABR (auditory brainstem response) testing. Regular follow-up of cranial nerve function is important for early detection of complications.


10. Treatment

Treatment of osteopetrosis differs greatly by type and causative gene, and in the AR malignant form HSCT is the only curative treatment.

Hematopoietic stem cell transplantation (HSCT): The only curative treatment for AR malignant osteopetrosis. HSCT transplants normal osteoclast precursor cells (derived from hematopoietic stem cells) from a donor, and after transplantation, osteoclasts with normal function are generated, restoring bone resorption. An HLA-identical sibling (matched sibling donor, MSD) gives the best results, and outcomes of matched unrelated donor (MUD) HSCT are also steadily improving. The optimal timing of HSCT is before cranial nerve damage (especially blindness) occurs, so early diagnosis and prompt HSCT are key. Cranial nerve damage that has already progressed is difficult to recover fully even after HSCT. In the AR malignant form with TCIRG1 or CLCN7 mutations, 5-year survival after HSCT is reported as about 70~80% with HLA-identical sibling donors and about 40~60% with unrelated donors. In the RANKL/RANK-deficient form and the OSTM1 mutation form, HSCT is of limited or no benefit, so other treatment strategies are needed.

Hematopoietic supportive care: Before HSCT or while awaiting HSCT, red blood cell transfusion for anemia, platelet transfusion for bleeding due to thrombocytopenia, antibiotic and antifungal prophylaxis to prevent infection due to neutropenia, and G-CSF (granulocyte colony-stimulating factor) administration are needed. TMP-SMX prophylaxis to prevent PCP (Pneumocystis jirovecii pneumonia) is standard.

Interferon-γ (IFN-γ): An effect of indirectly stimulating osteoclast function and partially improving bone resorption has been reported in some patients. It is sometimes used as a temporary treatment in patients for whom HSCT is not possible, but it is not a curative treatment.

Calcitriol (1,25-OH vitamin D): It has the effect of stimulating osteoclast differentiation and function, and is used as an adjunct in some patients in combination with IFN-γ.

Cranial nerve decompression: When compression of the optic canal or auditory nerve progresses, surgical decompression (optic canal decompression) is considered. However, when nerve damage has already progressed, recovery of vision after surgery is incomplete, and because the surgical risk is high, it should be performed at a specialized center.

Treatment of the AD benign form: No treatment is needed when asymptomatic. Calcium and vitamin D supplementation for hypocalcemia, orthopedic fixation for fractures, antibiotics and surgical management for mandibular osteomyelitis (prophylactic antibiotics at tooth extraction), and decompression surgery when cranial nerve compression progresses are performed individually.

Gene therapy (research stage): Gene therapy introducing a normal TCIRG1 or CLCN7 gene into hematopoietic stem cells with a viral vector is at the preclinical and early clinical trial stage and is expected to become a treatment that can replace or complement HSCT in the future.


11. Prognosis

The prognosis of osteopetrosis differs starkly by type.

Prognosis of the AR malignant (infantile) form: Without treatment (HSCT), most patients die before age 10. The main causes of death are recurrent infections (neutropenia), bleeding (thrombocytopenia) and cardiopulmonary complications. When HSCT is performed in time (before cranial nerve damage, if possible within 6 months of age), long-term survival with HLA-identical sibling donor HSCT reaches about 70~80%. Survival is also improving with unrelated donor HSCT owing to advances in conditioning regimens and transplant techniques. Major long-term complications after HSCT include graft-versus-host disease (GVHD), hepatic veno-occlusive disease (VOD) and infection. Because optic nerve damage that has already occurred recovers incompletely even after HSCT, early diagnosis is the most important factor determining prognosis.

Prognosis of the RANKL/RANK-deficient form: Because it does not respond to HSCT, the prognosis is especially poor, and research-stage treatments such as administration of recombinant RANKL are the only hope. The OSTM1 mutation form also has continued neurological progression after HSCT, so its prognosis is poorer than other AR forms.

Prognosis of the AD benign form: Life expectancy does not differ greatly from that of the general population. Recurrent fractures, mandibular osteomyelitis and cranial nerve complications can reduce quality of life but can be managed with active symptomatic treatment. If cranial nerve compression progresses, permanent hearing loss or reduced vision may occur, so regular monitoring is important.

Prognosis of the CAII-deficient form: Osteopetrosis, renal tubular acidosis and cerebral calcification are combined, but intellectual function varies. Correction of renal tubular acidosis (potassium citrate, etc.) partially improves growth and bone metabolism.


12. Prevention

The occurrence of osteopetrosis itself cannot be prevented other than through genetic counseling and prenatal diagnosis. Prevention of complications is clinically most important.

Genetic counseling and prenatal diagnosis: In families of patients with the AR malignant form (both parents carriers), genetic counseling before the next pregnancy and identification of an affected fetus through prenatal diagnosis (CVS or amniocentesis) or PGT-M are possible. After confirming whether the fetus is affected, appropriate planning is needed. Because patients with the AD benign form transmit the variant to their children with 50% probability, regular X-ray follow-up and clinical evaluation of the children are recommended.

Early diagnosis and prompt HSCT: The most important preventive intervention for the AR malignant form is performing HSCT after early diagnosis, before cranial nerve damage occurs. To this end, newborns with a family history should be evaluated immediately, and osteopetrosis must be included in the differential diagnosis of infantile pancytopenia.

Prevention of hypocalcemia: Because hypocalcemia before and after HSCT causes seizures and heart failure, serum calcium monitoring and calcium and vitamin D supplementation are essential.

Infection prevention: In neutropenic patients, infectious complications are minimized with PCP prophylaxis (TMP-SMX), antifungal prophylaxis and routine vaccinations (excluding live vaccines). In patients with the AD benign form, prophylactic antibiotics before tooth extraction or oral surgery are recommended to prevent mandibular osteomyelitis.

Optimizing the timing of cranial nerve decompression surgery: Progression of cranial nerve compression is detected early through regular ophthalmologic and audiologic evaluation, so that the optimal timing for surgical decompression is not missed. Because optic nerve compression is difficult to reverse once vision loss has progressed, early intervention is key.


13. References

  1. Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4:5. DOI: 10.1186/1750-1172-4-5. PMID: 19232085.

  2. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42(1):19-29. DOI: 10.1016/j.bone.2007.08.029. PMID: 17936076.

  3. Frattini A, Orchard PJ, Sobacchi C, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet. 2000;25(3):343-346. DOI: 10.1038/77131. PMID: 10888887.

  4. Kornak U, Kasper D, Bösl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205-215. DOI: 10.1016/S0092-8674(01)00206-9. PMID: 11207362.

  5. Orchard PJ, Fasth AL, Le Rademacher J, et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015;126(2):270-276. DOI: 10.1182/blood-2015-01-625541. PMID: 25985426.

  6. Sobacchi C, Schulz A, Coxon FP, et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-536. DOI: 10.1038/nrendo.2013.137. PMID: 23877423.

  7. Steward CG. Neurological aspects of osteopetrosis. Neuropathol Appl Neurobiol. 2003;29(2):87-97. DOI: 10.1046/j.1365-2990.2003.00459.x. PMID: 12662301.

  8. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004;351(27):2839-2849. DOI: 10.1056/NEJMra040952. PMID: 15625335.

  9. Lo Iacono N, Blair HC, Poliani PL, et al. Osteopetrosis rescue upon RANKL administration to RANKL-deficient mice: a new therapy for human RANKL-dependent ARO. J Bone Miner Res. 2012;27(12):2468-2476. DOI: 10.1002/jbmr.1712. PMID: 22826097.

  10. Nickels EM, Shi C, Kleta R, et al. Osteopetrosis — overview of disease spectrum, molecular mechanisms, and treatment. Curr Osteoporos Rep. 2021;19(4):339-352. DOI: 10.1007/s11914-021-00685-7. PMID: 33913102.